Trial Profile

Efficacy, Tolerability and Acceptability of the Single Table Regimen (STR) Biktarvy® by Trans People Living With HIV (TPLWH)

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 08 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
Indications HIV infections
Focus Therapeutic Use
Acronyms TPLWH

Most Recent Events

07 Feb 2024 This trail has been Prematurely Ended (Date : 2023-05-31) in Spain European Clinical trials database record.
23 May 2023 Status changed from recruiting to discontinued because trial set up was delayed, funding support no longer available.
03 May 2023 Planned End Date changed from 1 Oct 2023 to 1 Aug 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com